Moderna Q1: COVID-19 vaccine sales and Biologics License Application submission

Moderna has reported the first profitable quarter in the company’s history: after 10 years of research and several billion dollars of investment in its mRNA platform. The next step will be to start a rolling submission for a Biologics License Application (BLA) for its COVID-19 vaccine with the FDA this month.
Total revenue for the company was $1.9bn in Q1 (three months ended March 31, 2021): compared to $8m for the same period in 2020. Net income was $1.2bn for the quarter, compared to a net loss of $124m the year before.
Sales for 2021 are projected to total $19.2 billion. 
And looking forward, Moderna predicts that 2022 COVID-19 vaccine sales will exceed 2021’s sales.

Related Keywords

South Africa ,United States ,Israel ,Switzerland ,Brazil ,America , ,Pfizer ,Purchase Agreements ,Middle East ,Latin America ,Receptor Binding Domain ,N Terminal Domain ,ஒன்றுபட்டது மாநிலங்களில் ,இஸ்ரேல் ,சுவிட்சர்லாந்து ,பிரேசில் ,அமெரிக்கா ,ஃபைசர் ,நடுத்தர கிழக்கு ,லத்தீன் அமெரிக்கா ,ஏற்பி பிணைப்பு களம் ,ச்சனியான முனையத்தில் களம் ,